Actively Recruiting
Study of XL092 Zanzalintinib in Advanced Leiomyosarcoma, Bone Sarcoma, and Translocation-associated Soft Tissue Sarcoma
Led by Northwestern University · Updated on 2026-10-13
73
Participants Needed
1
Research Sites
260 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the drug zanzalintinib XL092 in a phase II trial for patients with advanced leiomyosarcoma, bone sarcoma, or translocation-associated soft tissue sarcoma that has spread or cannot be removed by surgery. Leiomyosarcomas are a type of sarcoma that can occur in various body locations, and current treatments offer limited progression-free survival of 4-6 months. XL092 is a tyrosine kinase inhibitor that may interfere with tumor growth by blocking cell communication. Participants receive XL092 orally once daily on days 1 through 14 of each 14-day cycle, continuing until the disease progresses or side effects become unacceptable. During the study, patients undergo echocardiography or multigated acquisition scans at screening and as needed, blood sample collections, and computed tomography scans. After finishing treatment, participants have a 30-day follow-up visit, then continue follow-up visits every 12 weeks for two years and every six months for up to five years. Throughout the trial, researchers monitor progression-free survival at six months as the primary outcome. Additional measures include overall survival, response rates, duration of response, and treatment-related side effects. Participants will be closely evaluated with imaging and laboratory tests to assess the study drugs impact and safety over time, with total participation lasting up to five years from treatment start.
CONDITIONS
Brief Title
XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma
Research Team
C
Coordinator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here